Biotilsvarende legemidler ved inflammatorisk tarmsykdom

Tidsskrift for den Norske Laegeforening

Volumn 134, Issue 8, 2014, Pages 819-820

  Moum, Bjørn ^a   Lundin, Knut E A ^b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; ECONOMICS; HUMAN; INFLAMMATORY BOWEL DISEASE; STANDARD; THERAPEUTIC EQUIVALENCE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; BIOSIMILAR PHARMACEUTICALS; HUMANS; INFLAMMATORY BOWEL DISEASES; THERAPEUTIC EQUIVALENCY;

EID: 84899519233     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: 10.4045/tidsskr.14.0192     Document Type: Note

References (4)

1. European Medicines Agency (EMA). Guideline on similar biological medicinal products containing monoclonal antibodies-non-clinical and clinical issues. http://ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf (21.3.2014).
2. Danese S, Gomollon F. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohn's Colitis 2013; 7: 586-9.
3. Legemiddelinnkjøpssamarbeidet. LIS-TNF/BIO-avtaler 2013. http://lisnorway.no/sider/tekst.asp?side=64 (17.3.2014).
4. Legemiddelinnkjøpssamarbeidet. LIS-TNF-BIOanbefalinger-2014. http://lisnorway.no/lisnorway/vedlegg/LIS-TNF-BIO-anbefalinger-2014.pdf (17.3.2014).